Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clark Nardinelli

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|July 4, 2008
Drug-review deadlines and safety problemsClark Nardinelli, Michael Lanthier, Robert Temple
Personalized Medicine|May 23, 2018
Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarinAndrew McWilliam, Randall Lutter, Clark Nardinelli
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
Health Economics|March 12, 2014
Estimating the benefits of public health policies that reduce harmful consumptionElizabeth M Ashley, Clark Nardinelli, Rosemarie A Lavaty
Health Affairs (Project Hope)|August 7, 2013
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011Michael Lanthier, Kathleen L Miller, Clark Nardinelli, et al.
Health Affairs (Project Hope)|May 9, 2012
Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still lowDongyi Du, John Goldsmith, Kathryn J Aikin, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|January 6, 2015
The Per Case and Total Annual Costs of Foodborne Illness in the United StatesTravis Minor, Angela Lasher, Karl Klontz, et al.
Medical Care|October 11, 2012
Atomoxetine use during a period of FDA actionsDongyi Tony Du, Esther H Zhou, John Goldsmith, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|July 4, 2008
Drug-review deadlines and safety problemsClark Nardinelli, Michael Lanthier, Robert Temple
Personalized Medicine|May 23, 2018
Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarinAndrew McWilliam, Randall Lutter, Clark Nardinelli
Nature Reviews. Drug Discovery|July 26, 2008
Economic issues with follow-on protein productsMichael Lanthier, Rachel Behrman, Clark Nardinelli
Health Economics|March 12, 2014
Estimating the benefits of public health policies that reduce harmful consumptionElizabeth M Ashley, Clark Nardinelli, Rosemarie A Lavaty
Health Affairs (Project Hope)|August 7, 2013
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011Michael Lanthier, Kathleen L Miller, Clark Nardinelli, et al.
Health Affairs (Project Hope)|May 9, 2012
Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still lowDongyi Du, John Goldsmith, Kathryn J Aikin, et al.
Drug Safety|March 26, 2017
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety WithdrawalsAndreas Schick, Kathleen L Miller, Michael Lanthier, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|January 6, 2015
The Per Case and Total Annual Costs of Foodborne Illness in the United StatesTravis Minor, Angela Lasher, Karl Klontz, et al.
Medical Care|October 11, 2012
Atomoxetine use during a period of FDA actionsDongyi Tony Du, Esther H Zhou, John Goldsmith, et al.
Pageof 1